1211515-16-0 Usage
General Description
2-chloro-5-fluoro-4-Methoxypyridine, also known as CFM, is a chemical compound with the molecular formula C6H5ClFNO. It is a pale yellow liquid that is primarily used as an intermediate in the production of pharmaceuticals, agrochemicals, and specialty chemicals. CFM is a versatile building block in the synthesis of various compounds, and it is known for its reactivity and selectivity in organic reactions. Its functional groups enable it to participate in a wide range of chemical reactions and make it a valuable component in the synthesis of diverse chemical compounds. CFM is also used as a research chemical in the development of new drugs and materials. However, it is important to handle CFM with care due to its potential health and safety hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 1211515-16-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,1,5,1 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1211515-16:
(9*1)+(8*2)+(7*1)+(6*1)+(5*5)+(4*1)+(3*5)+(2*1)+(1*6)=90
90 % 10 = 0
So 1211515-16-0 is a valid CAS Registry Number.
1211515-16-0Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE
-
, (2021/06/04)
The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase ("D5D"). The compounds have a general Formula (I): wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
-
Page/Page column 123, (2016/07/27)
The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.
